Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Vaccines |
Free Subscription
2 Ann Intern Med |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Vaccines is free of charge.
Resurgence of Dengue in the Era of Genomic Surveillance and Vaccines.
Ann Intern Med. 2024 Mar 19. doi: 10.7326/M24-0496.
PubMed
Clinical Outcomes With Electronic Nudges to Increase Influenza Vaccination : A
Prespecified Analysis of a Nationwide, Pragmatic, Registry-Based, Randomized
Implementation Trial.
Ann Intern Med. 2024 Mar 19. doi: 10.7326/M23-2638.
PubMed
Abstract available
RSV: Paediatricians call on government to expedite infant vaccination programme.
BMJ. 2024;384:q706.
PubMed
How climate change is changing vaccination planning.
BMJ. 2024;384:q360.
PubMed
Re-emergence of Diphtheria after COVID-19 Pandemic in Pakistan: time to consider
booster vaccination strategies.
J Infect. 2024 Mar 19:106141. doi: 10.1016/j.jinf.2024.106141.
PubMed
Strong cross immune responses against sarbecoviruses but not merbecoviruses in
SARS-CoV-2 BA.5/BF.7-infected individuals with or without inactivated COVID-19
vaccination.
J Infect. 2024;88:106138.
PubMed
Safety and Immunogenicity of the mRNA-1273 COVID-19 Vaccine in Solid Organ
Transplant Recipients.
J Infect Dis. 2024 Mar 21:jiae140. doi: 10.1093.
PubMed
Abstract available
Estimated population-level impact of pneumococcal conjugate vaccines against
all-cause pneumonia mortality among unvaccinated age groups in five Latin
American countries.
J Infect Dis. 2024 Mar 19:jiae144. doi: 10.1093.
PubMed
Abstract available
Outpatient visits and antibiotic use due to higher valency pneumococcal vaccine
serotypes.
J Infect Dis. 2024 Mar 18:jiae142. doi: 10.1093.
PubMed
Abstract available
Restoration of virulence in the attenuated Candid#1 vaccine virus requires
reversion at both positions 168 and 427 in the envelope glycoprotein GPC.
J Virol. 2024 Mar 20:e0011224. doi: 10.1128/jvi.00112.
PubMed
Abstract available
The varying extent of humoral and cellular immune responses to either vector- or
RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent
of infection.
J Virol. 2024 Mar 19:e0191223. doi: 10.1128/jvi.01912.
PubMed
Abstract available
Antigenic commonality and divergence of hemagglutinin-esterase-fusion protein
among influenza D virus lineages revealed using epitope mapping.
J Virol. 2024 Feb 12:e0190823. doi: 10.1128/jvi.01908.
PubMed
Abstract available
Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin
protein confers broad protection against H5Ny influenza viruses.
J Virol. 2024 Feb 2:e0112923. doi: 10.1128/jvi.01129.
PubMed
Abstract available
Postmarketing Vaccine Safety Assessments: Important Work in Progress.
JAMA. 2024;331:915-917.
PubMed
Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults.
JAMA. 2024;331:938-950.
PubMed
Abstract available
Recombinant Influenza Vaccine in Adults under 65 Years of Age.
N Engl J Med. 2024;390:1155.
PubMed
Recombinant Influenza Vaccine in Adults under 65 Years of Age.
N Engl J Med. 2024;390:1155-1156.
PubMed
Recombinant Influenza Vaccine in Adults under 65 Years of Age. Reply.
N Engl J Med. 2024;390:1156.
PubMed
Efficacy of Rotavirus Vaccines.
Pediatr Infect Dis J. 2024 Mar 20. doi: 10.1097/INF.0000000000004319.
PubMed
A Phase 3, Single-Arm Trial to Evaluate the Safety and Immunogenicity of a
20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through
<18 Years of Age.
Pediatr Infect Dis J. 2024 Mar 15. doi: 10.1097/INF.0000000000004318.
PubMed
Abstract available
Pediatric Otitis Media in the New Pneumococcal Conjugate Vaccines Era: What's
Next?
Pediatr Infect Dis J. 2024 Mar 15. doi: 10.1097/INF.0000000000004323.
PubMed
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus
bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy
adults without HIV (HVTN 107): A phase 1/2a randomized trial.
PLoS Med. 2024;21:e1004360.
PubMed
Abstract available
A theory-based assessment of mpox: Findings from a nationally representative
survey of U.S. adults.
PLoS One. 2024;19:e0299599.
PubMed
Abstract available
Factors associated with COVID-19 among hospitalized patients with severe acute
respiratory infections in Serbia, 2022-2023: A test negative case-control study.
PLoS One. 2024;19:e0299210.
PubMed
Abstract available
Oncolytic vaccinia virus immunotherapy antagonizes image-guided radiotherapy in
mouse mammary tumor models.
PLoS One. 2024;19:e0298437.
PubMed
Abstract available
How does collectivism help deal with perceived vaccine artificiality? The case of
COVID-19 vaccination intent in European young adults.
PLoS One. 2024;19:e0300814.
PubMed
Abstract available
Protocol for a community-based digital storytelling pilot intervention to reduce
Hispanic parents' vaccine hesitancy to immunize their children against COVID-19.
PLoS One. 2024;19:e0299787.
PubMed
Abstract available
Correction: Enhancing Specific-Antibody Production to the ragB Vaccine with GITRL
That Expand Tfh, IFN-gamma+ T Cells and Attenuates Porphyromonas gingivalis Infection
in Mice.
PLoS One. 2024;19:e0301151.
PubMed
Abstract available
Web-based survey investigating cardiovascular complications in hypermobile
Ehlers-Danlos syndrome after COVID-19 infection and vaccination.
PLoS One. 2024;19:e0298272.
PubMed
Abstract available
Exploring trends and determinants of basic childhood vaccination coverage:
Empirical evidence over 41 years.
PLoS One. 2024;19:e0300404.
PubMed
Abstract available
AE-GPT: Using Large Language Models to extract adverse events from surveillance
reports-A use case with influenza vaccine adverse events.
PLoS One. 2024;19:e0300919.
PubMed
Abstract available
Correction: Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma
gondii.
PLoS One. 2024;19:e0301214.
PubMed
Abstract available
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants
Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration,
symptom severity and viral kinetics, irrespective of vaccination history.
PLoS One. 2024;19:e0294897.
PubMed
Abstract available
Risk factors for critical COVID-19 illness during Delta- and Omicron-predominant
period in Korea; using K-COV-N cohort in the National health insurance service.
PLoS One. 2024;19:e0300306.
PubMed
Abstract available
Differences in social media use by COVID-19 vaccination status.
Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA
vaccines in adolescent/young adults with cancer: A prospective cohort study.
Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
The influence of health service interactions and local policies on vaccination
decision-making in immigrant women: A multi-site Canadian qualitative study.
Vaccine. 2024 Mar 20:S0264-410X(24)00299-8. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Yellow fever neutralizing antibody seroprevalence proportion and titers in
previously vaccinated adults with chronic kidney disease.
Vaccine. 2024 Mar 20:S0264-410X(24)00316-5. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Subolesin knockdown in tick cells provides insights into vaccine protective
mechanisms.
Vaccine. 2024 Mar 19:S0264-410X(24)00278-0. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Humoral and cellular immune responses induced by serogroup W135 meningococcal
conjugate and polysaccharide vaccines.
Vaccine. 2024 Mar 19:S0264-410X(24)00326-8. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Transformative vaccination: A pentavalent shield against COVID-19 and influenza
with betulin-based adjuvant for enhanced immunity.
Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.
PubMed
Abstract available
Is vaccination against measles, mumps, and rubella associated with reduced rates
of antibiotic treatments among children below the age of 2 years? Nationwide
register-based study from Denmark, Finland, Norway, and Sweden.
Vaccine. 2024 Mar 19:S0264-410X(24)00313-X. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
CHO cells for virus-like particle and subunit vaccine manufacturing.
Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Comparison of the safety and efficacy of the wild-type and lpxL/lpxM mutant
inactivated vaccine against the avian pathogenic Escherichia coli O1, O2, and O78
challenge.
Vaccine. 2024 Mar 18:S0264-410X(24)00325-6. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Measles vaccination coverage and immunization status of nurses: An interventional
study in Turkiye.
Vaccine. 2024 Mar 18:S0264-410X(24)00324-4. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Vaccine value profile for Klebsiella pneumoniae.
Vaccine. 2024 Mar 18:S0264-410X(24)00248-2. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
High throughput AS LNA qPCR method for the detection of a specific mutation in
poliovirus vaccine strains.
Vaccine. 2024 Mar 18:S0264-410X(24)00130-0. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Rabies importation in dogs and reduction of waiting period - The fear for
scientifically justified changes.
Vaccine. 2023 Oct 20:S0264-410X(23)01043-5. doi: 10.1016/j.vaccine.2023.
PubMed
Surveillance of pneumococcal serotypes in adults hospitalised with acute lower
respiratory tract infection in Bristol, UK.
Vaccine. 2024;42:1599-1607.
PubMed
Abstract available
Probability of exposure to the wild measles virus in adult population -
Estimation from seroepidemiology and historical data.
Vaccine. 2024;42:1648-1655.
PubMed
Abstract available
Immunogenicity and protective efficacy of RipA, a peptidoglycan hydrolase,
against Mycobacterium tuberculosis Beijing outbreak strains.
Vaccine. 2024;42:1941-1952.
PubMed
Abstract available
Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for
data collection, analysis, and presentation of immunisation safety data.
Vaccine. 2024 Feb 16:S0264-410X(24)00021-5. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
The association between BCG scars and self-reported chronic diseases: A
cross-sectional observational study within an RCT of Danish health care workers.
Vaccine. 2024;42:1966-1972.
PubMed
Abstract available
Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults
in United States commercial and Medicare claims databases, 2017-2020.
Vaccine. 2024;42:2004-2010.
PubMed
Abstract available
Post-marketing surveillance of intussusception after Rotarix administration in
Afghanistan, 2018-2022.
Vaccine. 2024;42:2059-2064.
PubMed
Abstract available
Impact of pneumococcal conjugate vaccination on pneumococcal nasopharyngeal
carriage in the Gambia: Population-based cross-sectional surveys.
Vaccine. 2024 Mar 14:S0264-410X(24)00225-1. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Identifying trusted local sources and predicting behavior change pathways
according to COVID-19 vaccination status: Results of a 2022 statewide survey of
Alaskan adults.
Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Do boys have the same intentions to get the HPV vaccine as girls? Knowledge,
attitudes, and intentions in France.
Vaccine. 2024 Mar 14:S0264-410X(24)00256-1. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
The effect of SARS-COV-2 variant on non-respiratory features and mortality among
vaccinated and non-fully vaccinated patients.
Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Lymphatic distribution considerations for subunit vaccine design and development.
Vaccine. 2024 Mar 16:S0264-410X(24)00320-7. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
Safety and immunogenicity of a novel trivalent recombinant MVA-based equine
encephalitis virus vaccine: A Phase 1 clinical trial.
Vaccine. 2024 Mar 16:S0264-410X(24)00296-2. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
COVID-19 vaccination in cancer patients: Immune responses one year after the
third dose.
Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024.
PubMed
Abstract available
The investigation of the dynamics of changes in neutralizing antibody titers
against type 5 adenovirus in the context of vaccination against a new coronavirus
infection.
Virology. 2024;594:110051.
PubMed
Abstract available
Thank you for your interest in scientific medicine.